TCL Archive Seer Places Survival Now at Least At 45 Percent, Could Be As High As 50 Percent For 1973-79 Patients December 4, 1981
TCL Archive Cancer Funding To Defense Dept. Is Threat To National Cancer Program, Broder Says March 5, 1993
TCL Archive FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says. January 14, 2005
TCL Archive In Brief: Frozen Panels Available to Evaluate diagnostic Assays; Panel to Meet at Johns Hopkins April 22 March 15, 1985
